首页> 外文期刊>The Quarterly Journal of Nuclear Medicine >Tracers and contrast agents in cardiovascular imaging: present and future
【24h】

Tracers and contrast agents in cardiovascular imaging: present and future

机译:心血管成像中的示踪剂和造影剂:现在和将来

获取原文
获取原文并翻译 | 示例
           

摘要

This brief article addresses the current status and future potential of nuclear medicine, X-ray computed tomography (CT), ultrasound (US), and magnetic resonance (MR) imaging in the diagnosis of cardiovascular diseases. The currently perceived advantages and disadvantages, as well as the possible future roles, of each of the modalities with regard to the evaluation of coronary artery disease are delineated. The certain advent of MR and US myocardial contrast agents, combined with the inexorable pressures of health care reform, will alter the future usage patterns of all four modalities. Future debates about which modality should be used in which clinical situation will be based not on "anatomy vs function", nor on which speciality owns which "turf, but rather on the issues of cost effectiveness and patient outcomes.
机译:这篇简短的文章探讨了核医学,X射线计算机断层扫描(CT),超声(US)和磁共振(MR)成像在心血管疾病诊断中的现状和未来潜力。概述了每种方法在评估冠状动脉疾病方面的当前优缺点和可能的未来作用。 MR和US心肌造影剂的某些问世,再加上医疗改革的巨大压力,将改变这四种方式的未来使用方式。关于在哪种临床情况下应使用哪种方式的未来辩论将不基于“解剖与功能”,也不基于哪个专业拥有“草坪”,而是基于成本效益和患者结果的问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号